Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli.

@article{Engebretsen2013LumicanII,
  title={Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli.},
  author={Kristin Victoria Tunheim Engebretsen and Ida Gjervold Lunde and Mari E. Strand and Anne Waehre and Ivar Sjaastad and Henriette S Marstein and Biljana Skrbic and Christen Peder Dahl and Erik Tandberg Askevold and Geir Christensen and Johannes Bj\ornstad and Theis T\onnessen},
  journal={The FEBS journal},
  year={2013},
  volume={280 10},
  pages={2382-98}
}
During progression to heart failure (HF), myocardial extracellular matrix (ECM) alterations and tissue inflammation are central. Lumican is an ECM-localized proteoglycan associated with inflammatory conditions and known to bind collagens. We hypothesized that lumican plays a role in the dynamic alterations in cardiac ECM during development of HF. Thus, we examined left ventricular cardiac lumican in a mouse model of pressure overload and in HF patients, and investigated expression, regulation… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 11 times over the past 90 days. VIEW TWEETS